Allogene Therapeutics Overview

Allogene Therapeutics Other Income Expense Net

Other Income/Expense Net for ALLO.

Quarterly Other Income/Expense

$3.48M

↓ 36.15% YoY

As of Mar 31, 2026

Annual Other Income/Expense (TTM)

$16.46M

↑ 36.94% YoY

Trailing 12 months ending Mar 31, 2026

Average Other Income/Expense (Comparison Companies)

Other Income Expense Net History

Other Income Expense Net Comparison

Jump to metric

Total Revenue Cost of Revenue Gross Profit Research & Development Selling, General & Admin Operating Income Other Income Expense Net EBIT Income Tax Net Income Profit Margin